0.34
-0.2221(-39.66%)
Currency In USD
| Previous Close | 0.56 |
| Open | 0.36 |
| Day High | 0.38 |
| Day Low | 0.33 |
| 52-Week High | 19.74 |
| 52-Week Low | 0.33 |
| Volume | 3.23M |
| Average Volume | 3.62M |
| Market Cap | 1.15M |
| PE | -0.04 |
| EPS | -8.64 |
| Moving Average 50 Days | 0.64 |
| Moving Average 200 Days | 1.64 |
| Change | -0.22 |
AIM ImmunoTech Announces Closing of its Rights Offering
GlobeNewswire Inc.
Mar 07, 2026 12:00 AM GMT
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
GlobeNewswire Inc.
Mar 04, 2026 2:00 PM GMT
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
GlobeNewswire Inc.
Mar 02, 2026 2:00 PM GMT
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3